Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

93 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Unexpected high incidence of hepatocellular carcinoma in cirrhotic patients with sustained virologic response following interferon-free direct-acting antiviral treatment.
Kozbial K, Moser S, Schwarzer R, Laferl H, Al-Zoairy R, Stauber R, Stättermayer AF, Beinhardt S, Graziadei I, Freissmuth C, Maieron A, Gschwantler M, Strasser M, Peck-Radosalvjevic M, Trauner M, Hofer H, Ferenci P. Kozbial K, et al. Among authors: maieron a. J Hepatol. 2016 Oct;65(4):856-858. doi: 10.1016/j.jhep.2016.06.009. Epub 2016 Jun 16. J Hepatol. 2016. PMID: 27318327 No abstract available.
Performance of T-Track® TB, a Novel Dual Marker RT-qPCR-Based Whole-Blood Test for Improved Detection of Active Tuberculosis.
Meier JP, Möbus S, Heigl F, Asbach-Nitzsche A, Niller HH, Plentz A, Avsar K, Heiß-Neumann M, Schaaf B, Cassens U, Seese B, Teschner D, Handzhiev S, Graf U, Lübbert C, Steinmaurer M, Kontogianni K, Berg C, Maieron A, Blaas SH, Wagner R, Deml L, Barabas S. Meier JP, et al. Among authors: maieron a. Diagnostics (Basel). 2023 Feb 16;13(4):758. doi: 10.3390/diagnostics13040758. Diagnostics (Basel). 2023. PMID: 36832246 Free PMC article.
A randomized, prospective trial of ribavirin 400 mg/day versus 800 mg/day in combination with peginterferon alfa-2a in hepatitis C virus genotypes 2 and 3.
Ferenci P, Brunner H, Laferl H, Scherzer TM, Maieron A, Strasser M, Fischer G, Hofer H, Bischof M, Stauber R, Gschwantler M, Steindl-Munda P, Staufer K, Löschenberger K; Austrian Hepatitis Study Group. Ferenci P, et al. Among authors: maieron a. Hepatology. 2008 Jun;47(6):1816-23. doi: 10.1002/hep.22262. Hepatology. 2008. PMID: 18454510 Clinical Trial.
Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response.
Ferenci P, Laferl H, Scherzer TM, Gschwantler M, Maieron A, Brunner H, Stauber R, Bischof M, Bauer B, Datz C, Löschenberger K, Formann E, Staufer K, Steindl-Munda P; Austrian Hepatitis Study Group. Ferenci P, et al. Among authors: maieron a. Gastroenterology. 2008 Aug;135(2):451-8. doi: 10.1053/j.gastro.2008.04.015. Epub 2008 May 27. Gastroenterology. 2008. PMID: 18503773 Clinical Trial.
Peginterferon alfa-2a/ribavirin for 48 or 72 weeks in hepatitis C genotypes 1 and 4 patients with slow virologic response.
Ferenci P, Laferl H, Scherzer TM, Maieron A, Hofer H, Stauber R, Gschwantler M, Brunner H, Wenisch C, Bischof M, Strasser M, Datz C, Vogel W, Löschenberger K, Steindl-Munda P; Austrian Hepatitis Study Group. Ferenci P, et al. Among authors: maieron a. Gastroenterology. 2010 Feb;138(2):503-12, 512.e1. doi: 10.1053/j.gastro.2009.10.058. Epub 2009 Nov 10. Gastroenterology. 2010. PMID: 19909752 Clinical Trial.
[4. Austrian consensus-statement for diagnosis and therapy of hepatitis B 2009].
Peck-Radosavljevic M, Deutsch J, Ferenci P, Graziadei I, Hofer H, Holzmann H, Huber WD, Laferl H, Maieron A, Stauber R, Vogel W. Peck-Radosavljevic M, et al. Among authors: maieron a. Wien Klin Wochenschr. 2010 May;122(9-10):280-302. doi: 10.1007/s00508-009-1298-0. Epub 2010 May 4. Wien Klin Wochenschr. 2010. PMID: 20443069 German.
93 results